Dr. Dadu on Current Treatment Approaches in Anaplastic Thyroid Cancer

Ramona Dadu, MD
Published Online: Thursday, Sep 29, 2016



Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the current treatment approaches being evaluated for patients with anaplastic thyroid cancer (ATC).

While there are approved treatments in this setting, Dadu says that most of them do not demonstrate very efficacious results for patients. Therefore, clinical trials often serve as first-line therapies for metastatic ATC.

Targeted therapies have been explored in this setting, though recent results have shown quite short progression-free survival (PFS) rates. Perhaps adding immunotherapy to targeted therapy, explains Dadu, will lead to improved PFS and overall survival rates.


Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the current treatment approaches being evaluated for patients with anaplastic thyroid cancer (ATC).

While there are approved treatments in this setting, Dadu says that most of them do not demonstrate very efficacious results for patients. Therefore, clinical trials often serve as first-line therapies for metastatic ATC.

Targeted therapies have been explored in this setting, though recent results have shown quite short progression-free survival (PFS) rates. Perhaps adding immunotherapy to targeted therapy, explains Dadu, will lead to improved PFS and overall survival rates.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Redefining Treatment Paradigms in the Management of Chronic Lymphocytic LeukemiaOct 05, 20172.0
Community Practice Connections: 15th Annual International Congress on the Future of Breast Cancer®Oct 06, 20172.0
Publication Bottom Border
Border Publication